MCM
TSHA icon

Militia Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Militia Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Hold
46,500
– – 0.01% 253
2026
Q1 		$208K Buy
+46,500
New +$216K 0.02% 260

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Militia Capital Management's TSHA Position: Q2 2026 in Review

Militia Capital Management held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 46,500 shares worth $317K. The position accounts for 0.01% of the portfolio, ranked #253.

Militia Capital Management first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Militia Capital Management held 46,500 shares of Taysha Gene Therapies worth $317K as of Q2 2026.
  • Militia Capital Management left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up 0.01% of Militia Capital Management's portfolio in Q2 2026, its #253 holding.
  • Militia Capital Management first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Militia Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.